Nathan Kastelein discusses the new Stereotaxis MAGiC Sweep EP mapping catheter's design, development and use of magnets.
Zacks Investment Research on MSN
How Will DefenCath Aid CRMD's Top Line in the Upcoming Q3 Results?
CorMedix’s CRMD DefenCath (Taurolidine + Heparin) is its lead marketed product and the primary revenue driver for the company. The FDA approved DefenCath in late 2023 as the first and only ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback